Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Bortezomib is a proteasome inhibitor with remarkable preclinical and clinical antitumor activity in multiple myeloma (MM) patients. The initial rationale for its use in MM was inhibition of nuclear factor (NF)-κB activity by blocking proteasomal degradation of inhibitor of κBα (IκBα). Bortezomib inh...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Hideshima, Teru, Ikeda, Hiroshi, Chauhan, Dharminder, Okawa, Yutaka, Raje, Noopur, Podar, Klaus, Mitsiades, Constantine, Munshi, Nikhil C., Richardson, Paul G., Carrasco, Ruben D., Anderson, Kenneth C.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2009
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721785/
https://ncbi.nlm.nih.gov/pubmed/19436050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-199604
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы